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 Abstract 
 Background: Newborn infants with risk factors may require intravenous (IV) dextrose for
asymptomatic hypoglycemia. Administration of IV dextrose and transfer to the neonatal in-
tensive care unit (NICU) may interfere with parent-infant bonding.  Objective: To study the 
effect of implementing dextrose gel supplement with feeds in late preterm/term infants af-
fected by asymptomatic hypoglycemia on reducing IV dextrose therapy.  Method: A retro-
spective study was conducted before and after dextrose gel use: 05/01/2014 to 10/31/2014 
and 11/01/2014 to 04/30/2015, respectively. Asymptomatic hypoglycemic (blood glucose lev-
el <45 mg/dl) infants in the newborn nursery (NBN) were given a maximum of 3 doses of 
dextrose gel (200 mg/kg of 40% dextrose) along with feeds. Transfer to the NICU for IV dex-
trose was considered treatment failure.  Results: Dextrose gel with feeds increased the blood 
glucose level in 184/250 (74%) of asymptomatic hypoglycemic infants compared to 144/248 
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 What Is It about? 
 Persistent asymptomatic hypoglycemia in newborns not responding to feeding often requires intra-
venous dextrose therapy. Previously, a randomized trial studied the use of 40% dextrose gel and feeds 
for asymptomatic hypoglycemia and showed reduction in the need for intravenous dextrose therapy 
with improved breastfeeding and maternal-infant bonding. We studied the impact of introducing a 
protocol for late-preterm/term asymptomatic hypoglycemic neonates incorporating supplementation 
of feeds with dextrose gel at a regional perinatal center in the United States. After implementation of 
the 40% dextrose gel, there was a reduction in intravenous dextrose therapy as well as reduced hospital 
costs and improved breastfeeding rates at discharge.
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(58%) with feeds only (p < 0.01). Transfer from the NBN to the NICU for IV dextrose decreased 
from 35/1,000 to 25/1,000 live births (p < 0.01). Exclusive breastfeeding improved from 19 to 
28% (p = 0.03).  Conclusions: Use of dextrose gel with feeds reduced the need for IV fluids, 
avoided separation from the mother and promoted breastfeeding. Neonates who failed dex-
trose gel therapy were more likely to be large for gestational age, delivered by cesarean sec-
tion and had lower baseline blood glucose levels.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Neonatal hypoglycemia is a global health problem and a preventable cause of neuro-
logical injury during the newborn period  [1–3] . Approximately 15% of neonates are at risk 
for neonatal hypoglycemia  [4] . Some of these infants fail to normalize their blood glucose 
level by feeds alone and require intravenous (IV) dextrose therapy. Preterm, small for gesta-
tional age (SGA) infants, infants of diabetic mothers and large for gestational age (LGA) infants 
are at high risk of requiring IV dextrose therapy due to persistent hypoglycemia. Many insti-
tutions, including ours, transfer neonates in need of IV dextrose from the newborn nursery 
(NBN) to the neonatal intensive care unit (NICU). This leads to separation of the baby from 
his/her mother, undue anxiety affecting bonding and breastfeeding, as well as contributing 
to increased hospitalization costs. Symptomatic infants with hypoglycemia require prompt 
glucose supplements preferably through the IV route to reduce symptoms and prevent long-
term sequelae. However, a large number of ‘at risk’ neonates screened for hypoglycemia are 
asymptomatic and are treated due to the association between prolonged hypoglycemia and 
neurological impairment  [3] . Approximately 10% of these asymptomatic neonates require 
admission to a NICU for the treatment of neonatal hypoglycemia adding an estimated USD 2.1 
billion to health care costs annually in the United States  [5] . Controversy still surrounds the 
definition, significance and management of neonatal hypoglycemia  [6] . There is limited scien-
tific evidence to guide treatment of asymptomatic neonatal hypoglycemia  [4] . A blood glucose 
level maintained at  ≥ 47 mg/dl is not associated with adverse neurological outcome and is 
generally considered a safe target after the first 4 h of postnatal age  [3] . Among adults, 40% 
dextrose gel is used for treating hypoglycemia  [7] . Harris and colleagues  [8] conducted a 
randomized, double-blind, placebo-controlled trial of 230 infants (115 infants randomized to 
dextrose gel and 115 to placebo) and concluded that treatment with 40% dextrose gel along 
with breastfeeding, expressed breast milk or formula was more effective than feeds alone and 
increased blood glucose levels. They recommended that dextrose gel be considered for first-
line management of late preterm and term hypoglycemic babies in the first 48 h after birth. 
A recent published meta-analysis had similar conclusions  [8] . Dextrose gel is inexpensive 
(USD 12.99 for 3 tubes of 15 g each or approximately USD 1 per dose of 1,200 mg/3 ml) and 
can be prepared by the hospital pharmacy. 
 We implemented a protocol including dextrose gel therapy for asymptomatic hypogly-
cemic infants at  ≥ 35 weeks postmenstrual age (PMA). Our objectives were to determine 
whether feeds supplemented with 40% dextrose gel are more effective than feeds alone in 
treating asymptomatic neonatal hypoglycemia in term and late preterm neonates in the first 
48 h after birth admitted to the NBN. We also evaluated the impact of this protocol on the 
number of NICU admissions for IV dextrose therapy.
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 Methods 
 This retrospective chart review was approved by the Children and Youth Institutional 
Review Board at the University at Buffalo.
 After a review of the existing literature on dextrose gel, a multidisciplinary committee 
added dextrose gel to the neonatal asymptomatic hypoglycemia protocol ( fig. 1 ). Dextrose
gel (40%, Glutose15 TM , Perrigo, Dublin, Ireland; ingredients: purified water, d-glucose USP 
40%, glycerin, lemon flavoring and Methylparaben NF in an oral gel base) was packaged into 
1,200 mg/3 ml doses in oral syringes and stocked in the Pyxis in the NBN. Weight-based 
dosing of dextrose gel was established with the help of the pharmacy (200 mg/kg or 0.5 ml/
kg applied to buccal mucosa; online suppl. video file; for all online suppl. material, see www.
karger.com/doi/10.1159/000448511).
????????????????? de??????????????? ??????????
??????? ???????????????????????????? ???
If this episode of hypoglycemia resolves but
there is then a second or third episode of
glucose <45 mg/dl, you may repeat the
dextrose gel ×2 for a maximum total of 
3 doses over a 24-hour period
Risk factors: less than 37 weeks, SGA, LGA, maternal diabetes, cord pH <7.10, cord base excess less than –10, axillary temperature <36ºC; mother on:
?-blockers (propranolol), ?-sympathomimetics (terbutaline), oral hypoglycemic agents (metformin, glucophage, glyburide), indomethacin, procardia
Birth to 4 h of age 4–48 h of age
Is the baby medically able to feed (OG or PO) in the 1st hour of life?
(If unlikely to be fed after 4 h of life, start IV glucose at birth)
Yes
Lab ?25 mg/dl
Lab >45 mg/dl Lab >45 mg/dl
i-STAT >45 mg/dl
i-STAT >45 mg/dli-STAT ?45 mg/dl
i-STAT <45 mg/dl*
notify provider
Lab <25 mg/dl
1. Breastfeed
    Attempt for 15 min, if unable, then
2. Hand expressor pump breast milk/colostrum then finger feed/dropper feed
    Attempt for 15 min, if unable to pump, then
3. 3–10 ml/kg of formula via SNS**
  **if mother has decided not to breastfeed, provide formula feed
Move to ‘4–48 h of age’
Order of feeding regimens
Lab 25–45 mg/dl Lab 25–45 mg/dl
Lab >25 mg/dl Lab >25 mg/dl
Not feeding
Lab ?25 mg/dl
Glucose screen <50 mg/dl
No
Not
feeding
Feeding
Feed within the 1st hour THEN
Screen glucose with glucometer 30 min after feed, and if <50 mg/dl,
confirm with i-STAT or lab (and feed the infant while waiting for lab result)
Feed first and add dextrose gel
200 mg/kg ×1 to buccal mucosa
Screen glucose 30 min after feeding
Feed every 1–3 h with
glucose screen after the
next feed
Feed every 1–3 h with
glucose screens 1 h after
each feed until 2 consecutive
readings >45 mg/dl 
Then screen Q6 h
before feeds for a total of 24 h
Provider notification
Feed first and add dextrose gel
200 mg/kg ×1 to 
buccal mucosa
Screen glucose in 30 min,
if glucose still <45 mg/dl start IV
glucose*
Screen glucose at 2 h of life
Recheck at 3 and 4 h of
life; begin feeds once baby
is able
Begin
IV glucose*
Begin
IV glucose*
Recheck in 1 h
OR
begin
IV glucose*
If feeding remains
contraindicated
beyond 4 h of life
begin
IV glucose*
Symptomatic
hypoglycemia ? STAT
IV dextrose
All glucose levels are
point-of-care (i-STAT) or
laboratory values unless
indicated.
Feed every 1–3 h with glucose screens Q6 h
before feeds until 24 h of stable glucose levels
(target glucose is >45 mg/dl prior to feeds)
IV glucose* Feed Q1–3 h with glucose
screens Q3 h before feeds 
until 24 h of stable glucose
Begin IV glucose* after the 4th episode
of hypoglycemia within 48 h
*Glucose dose = 200 mg/kg 
(dextrose 10% at 2 ml/kg) 
and/or IV infusion at 5–8 mg/kg/min 
(80–100 ml/kg/day)
Achieve plasma glucose level of 40–50 mg/dl
 Fig. 1. Newborn nursery protocol for the screening and management of asymptomatic hypoglycemia. OG = 
Orogastric; PO = per os; SNS = supplemental nursing system.  
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 Mandatory educational sessions were provided to all nurses that focused on the use of 
the new algorithm ( fig. 1 ) and the technique of administering the gel. This algorithm was 
implemented at the Regional Perinatal Center at the Women and Children’s Hospital of Buffalo 
and at an affiliated nursery at Millard Fillmore Suburban Hospital. The use of 40% dextrose 
gel was started in November 2014. 
 Hypoglycemia Guidelines 
 Two protocols were developed for the treatment of infants  ≥ 35 weeks PMA – one for 
symptomatic hypoglycemia (data not shown) and a second protocol for asymptomatic infants 
at risk for hypoglycemia.  Figure 1 shows the protocol used in our institution to treat asymp-
tomatic hypoglycemia.
 A maximum of 3 doses of dextrose gel were given during the first 48 h. If the blood glucose 
level was <25 mg/dl after the administration of dextrose gel, the infant was admitted to the 
NICU for IV dextrose therapy. At any point, if the baby developed symptoms secondary to 
hypoglycemia, a STAT mini-bolus (2 ml/kg of 10% dextrose IV) was administered and an IV 
10% dextrose infusion was initiated at 60–80 ml/kg/day.
 The study was conducted before and after implementation of the revised hypoglycemia 
algorithm with dextrose gel: 05/2014 to 10/2014 and 11/2014 to 04/2015. We included 
infants at risk for neonatal hypoglycemia, with the following criteria: infants <37 weeks of 
age, SGA and LGA, maternal diabetes, cord pH <7.10, cord base excess less than –10 mEq/l, as 
well as maternal treatment with β-blockers (propranolol), β-sympathomimetics (e.g., terbu-
taline), oral hypoglycemic agents (e.g., metformin, glyburide), indomethacin, or nifedipine. 
These infants were asymptomatic, 35 weeks PMA or greater and <48 h old. We excluded 
infants with symptomatic hypoglycemia and congenital malformations. If hypoglycemia 
resolved with dextrose gel but recurred within 48 h of postnatal age, therapy with dextrose 
gel could be repeated twice (to a maximum of 3 doses during the entire 48-hour period) 
( fig. 1 ). We did not include infants older than 48 h as they are at risk for persistent hypogly-
cemic disorders, and, also, the lower limit for the glucose threshold in these infants is 60 mg/
dl  [9] .
 Transfer to the NICU for IV dextrose was considered treatment failure and was the 
primary outcome. Secondary outcomes included exclusive breastfeeding rates at discharge 
and cost savings associated with the protocol for dextrose gel.
 The physician and hospital costs were obtained from the University at Buffalo, Department 
of Pediatrics practice plan and the Finance Department of the Women and Children’s Hospital 
and Millard Fillmore Suburban Hospital.
 Analysis 
 Categorical data were analyzed using the χ 2 test or Fisher’s exact test as appropriate. 
Continuous data were analyzed using the independent sample t test or the Wilcoxon-Mann-
Whitney test. Absolute risk reduction and the number needed to treat were calculated with 
confidence intervals (CI). For statistical significance, the probability was set at <5%. Analysis 
was performed with SPSS 22 (IBM, New York, N.Y., USA) and GraphPad (GraphPad Software 
Inc., La Jolla, Calif., USA)
 Results 
 Before and after Dextrose Gel Implementation 
 During the pre- and post-dextrose gel protocol implementation epochs, there was no 
difference in the number of live births, asymptomatic hypoglycemic infants, infants of diabetic 
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mothers, SGA or LGA infants. Furthermore, during the two periods, there was no difference 
in total admissions to the NICU ( table 1 ). However, the number of infants transferred from 
the NBN to the NICU for IV dextrose therapy significantly decreased with the implementation 
of the revised hypoglycemia algorithm with dextrose gel ( fig. 1 ).
 The number of infants transferred from the NBN to the NICU for hypoglycemia decreased 
from 35/1,000 to 25/1,000 live births (p < 0.01). As a percentage of all NICU admissions, 
those with an indication of asymptomatic hypoglycemia decreased from 20.6 to 14.8%. After 
introduction of dextrose gel, only 26% of asymptomatic hypoglycemic neonates in the NBN 
were transferred to the NICU for IV dextrose compared to 42% during the pre-dextrose gel 
epoch (feeds alone). The exclusive breastfeeding rates at hospital discharge improved signif-
icantly after introduction of dextrose gel ( table 1 ).
 Characteristics of Infants Treated with Oral Dextrose Gel  
 Infants who failed therapy with dextrose gel and required IV fluids were LGA, more likely 
to have been delivered by cesarean section and had lower blood glucose levels. The Apgar 
scores were similar between responders and nonresponders ( table 2 ). As expected, therapy 
with dextrose gel resulted in significantly higher blood glucose levels compared to nonre-
sponders. Following therapy with dextrose gel, the median glucose levels were 58 mg/dl (IQR 
45–86). Following IV dextrose therapy, the median glucose levels were 64 mg/dl (IQR 
45–120). The number of doses of dextrose gel required and the babies who responded with 
each dose are shown in  figure 2 . Seventy of the 184 responders required only one dose of 
dextrose gel ( fig. 2 ), while 28 of the 66 infants who failed therapy required IV dextrose therapy 
after the first dose. 
 Impact of Using Oral Dextrose Gel 
 The absolute risk reduction for IV dextrose therapy after the introduction of dextrose gel 
was 15.54% (95% CI 7.32–23.76). The number needed to treat was 7 (95% CI 4.2–13.7). The 
average length of stay for infants who required IV dextrose therapy was 7.3 ± 4.3 days. The 
average duration of IV dextrose therapy alone was 3.4 ± 2.6 days. The length of stay for 
neonates who responded to dextrose gel was 3.1 ± 1.1 days. With treatment success, the 
breastfeeding rates at discharge were higher among the responders.
 Table 1.  Characteristics of asymptomatic hypoglycemic infants before and after the implementation of oral dextrose gel
Characteristics May 1, 2014, to 
October  31, 2014 
(pre-dextrose gel epoch)
November 1, 2014, to
April 30, 2015
(post-dextrose gel epoch)
p value
Total live births 2,937 2,654 –
Total asymptomatic infants with hypoglycemia 248 (8.4) 250 (9.4) 0.20
Improved with feeds i n the pre-dextrose gel epoch/feeds + dextrose gel in
the post-dextrose gel epoch 144 (58) 184 (74) <0.01
Transferred to the NICU for IV dextrose 104 (42) 66 (26) <0.01
Maternal diabetes 74 (30) 70 (28) 0.69
LGA 48 (20) 33 (13) 0.06
SGA 34 (14) 37 (15) 0.80
Exclusive breastfeeding at hospital discharge 48 (19) 70 (28) 0.03
Overall total admissions to the NICU for all indications 503 (17) 454 (17) 1.0
Number of babies transferred from the NBN to the NICU for hypoglycemia 104 (21) 66 (14) 0.01
Figures in parentheses are percentages.
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 Economic Impact 
 The cost (physician billing and hospital charges) of care for asymptomatic infants with 
hypoglycemia in the newborn nursery (with feeds ± dextrose gel) and in the NICU with IV 
dextrose are shown in  tables 2 and  3 . The implementation of a protocol incorporating dextrose 
gel resulted in an overall cost savings of USD 642,951 over the 6-month period (or USD 2,593 
per patient with asymptomatic hypoglycemia).
 Discussion 
 This is the first report of an implementation of dextrose gel therapy for asymptomatic 
hypoglycemia in late preterm and term neonates at a regional perinatal center in the United 
States. We were successful in reducing the number of neonates requiring IV dextrose therapy 
and admission to the NICU, increasing exclusive breastfeeding at discharge and reducing 
health care costs.
 Infants who are persistently hypoglycemic (blood glucose level <45 mg/dl) and asymp-
tomatic in spite of feeds were treated with IV dextrose therapy to maintain euglycemia. 
Constant glucose infusion through dextrose therapy maintains the blood sugar, after which it 
is a common practice to wean IV fluids. IV dextrose therapy can also cause a rapid increase in 
 Table 2. Characteristics of infants based on glycemic response to dextrose gel
Characteristics Responders
(no IV fluids after 
dextrose gel)
Nonresponders
(IV fluids after 
dextrose gel)
p value
Total infants 184 (74) 66 (26) –
Maternal age, years 29 ± 6 30 ± 4 0.21
Maternal BMI 33.7 ± 8 35.6 ± 8 0.09
Maternal diabetes 47 (26) 24 (36) 0.12
Birth weight, g 2,905 ± 1,130 3,110 ± 1,173 0.21
Gestational age, weeks 38.6 ± 1.6 38.6 ± 1.3 0.98
Median Apgar score at 5 min (IQR) 9 (9 – 9) 9 (9 – 9) 1.0
LGA 18 (10) 15 (23) 0.02
SGA 44 (24) 22 (33) 0.15
Cesarean section 70 (38) 35 (53) 0.04
Exclusive breastfeeding 62 (34) 8 (12) <0.01
Blood glucose before the 1st dose of dextrose gel, mg/dl 39.7 ± 6 33.6 ± 9 <0.01
Blood glucose 1 h after the 1st dose of dextrose gel, mg/dl 54.7 ± 12.6 46.3 ± 10 <0.01
Physician and hospital charges per patient, USD 5,037 ± 853 36,391 ± 13,504 <0.01
Figures in parentheses are percentages, unless otherwise indicated.
 Table 3. Economic impact of using oral dextrose gel
Parameters Mean cost ± SD, 
USD
Cost for a NICU admission to treat hypoglycemia with IV dextrose therapy 31,820 ± 13,272
Cost for a regular NBN admission 4,415 ± 819
Cost for treating hypoglycemia successfully with oral dextrose gel 5,037 ± 873
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blood glucose level which can be potentially detrimental  [10] . The increase in the blood 
glucose level after dextrose gel administration was within the physiological range, with no 
episodes of hyperglycemia.
 Implementation of the revised hypoglycemia protocols included one grand rounds 
lecture followed by multiple in-service lectures by physician leaders, pharmacists and nurse 
educators. Compliance with the protocol increased rapidly during the first few days of imple-
mentation. The use of 40% dextrose gel was not associated with any adverse outcome or large 
fluctuations in blood glucose levels, which was consistent with the previous literature  [8, 11] .
 Prior to the introduction of dextrose gel therapy, many of our infants were supplemented 
with formula for asymptomatic hypoglycemia due to concerns about lack of colostrum. This 
was based on the evidence that most term infants who were breastfed had blood sugar levels 
less than those of infants who were formula fed  [12–14] . In the pre-intervention period, 
despite higher formula supplementation, the number of infants who required IV dextrose 
therapy was high compared to the post-dextrose gel epoch. After introducing dextrose gel and 
feeds together, the need for formula supplementation decreased, and exclusive breastfeeding 
rates at the time of discharge increased in these infants. A consistent result across the studies 
evaluating the use of dextrose gel is the improvement in exclusive breastfeeding rates  [15] . 
Our study found similar results in that breastfeeding rates prior to discharge improved with 
implementation of dextrose gel and was higher in those infants who responded to therapy. 
Interestingly, this intervention resulted in an improvement in the Consumer Assessment of 
Healthcare Providers and Systems (CAHPS) score (Press Ganey ® ). The percentage of mothers 
rating the hospital as 9–10 increased from 57.6% (22nd percentile for the New York state 
peer group) in the pre-dextrose gel epoch to 68.4% (72nd percentile for the New York peer 
group). Similarly, the percentage of mothers answering ‘definitely yes’ for recommending this 
hospital increased from 61.7% (31st percentile) to 76.1% (83rd percentile). We acknowledge 
that factors other than dextrose gel administration may have played a role in this improvement.
 Implementation of dextrose gel not only avoided the need for IV fluids but could also 
reduce the need for painful procedures such as venipuncture. Since oral glucose solution is 
used as comfort measures in the NICU, oral dextrose gel might also have mitigated the pain 
secondary to heel stick  [16] . Infants who did not respond to dextrose gel therapy in our study 
had lower initial blood glucose levels and were more likely to be LGA compared to responders. 
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 Fig. 2. Response to dextrose gel 
among 250 patients with asymp-
tomatic hypoglycemia managed 
with the hypoglycemia protocol 
shown in figure 1. Seventy pa-
tients responded to the first dose 
of dextrose gel and did not re-
quire further therapy. Twenty-
eight patients had low glucose 
levels of <25 mg/dl after the first 
dose of dextrose gel and were 
transferred to the NICU for IV 
dextrose treatment. 152 patients 
had glucose levels of 25–45 mg/dl 
and were treated with a second 
dose of dextrose gel. Response to 
the second and third dose of dex-
trose gel is also shown. 
8Biomed Hub 2016;1:448511 (DOI:10.1159/000448511)
 Rawat et al.: Oral Dextrose Gel Reduces the Need for Intravenous Dextrose Therapy in 
Neonatal Hypoglycemia 
www.karger.com/bmh
© 2016 The Author(s). Published by S. Karger AG, Basel
We speculate that these infants probably experienced hyperinsulinemic hypoglycemia as 
opposed to transitional hypoglycemia in infants appropriate for gestational age.
 Finally, the economic impact created by the introduction of oral dextrose gel therapy in 
reducing NICU admissions was quite significant. Although the number needed to treat was 7, 
there were substantial reductions in physician and hospital charges ( table 1 ). The majority of 
the infants who responded to oral dextrose gel therapy required only 1 dose. 
 Our study has several limitations. The comparison between feeds only and feeds and 
dextrose gel was not randomized but part of a pre- versus post-intervention study. In addition, 
during the pre-intervention period, data were collected retrospectively using the electronic 
medical record. After introduction of the dextrose gel, nurses and nurse practitioners recorded 
data in a prospective manner as part of this quality improvement project. Our initial blood 
glucose levels were obtained using a point-of-care glucometer which was later confirmed by 
the laboratory on a stat sample if the point-of-care blood sugar level was <45 mg/dl. Unlike 
many institutions, our nursery does not provide IV glucose, and a need for parenteral fluids 
necessitates the transfer to the NICU and escalates the health care cost. Our economic 
assessment does not cover the impact of breastfeeding. Finally, we did not have the follow-up 
data to see the breastfeeding rates after discharge.
 To conclude, therapy with dextrose gel can be effectively incorporated into the hypogly-
cemia protocol for asymptomatic late preterm and term infants. Our study confirms the 
findings of previous studies that dextrose gel is a less expensive alternative therapy that can 
reduce the need for IV dextrose therapy, increase breastfeeding rates and improve parent 
satisfaction probably due to maternal infant bonding. A future trial, such as the hypoglycemia 
prevention with oral dextrose gel (ACTRN 12614001263684)  [17] , will shed light on the 
economic impact of this therapy. Large randomized control trials (NCT02523222 and 
ACTRN12613000322730) are being planned and will give us further insight into dextrose gel 
therapy for asymptomatic hypoglycemia and neurodevelopmental outcomes.
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